Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Future Med Chem. 2015 Jun;7(8):1023–1038. doi: 10.4155/fmc.15.44

Figure 5. Darunavir and selected investigational inhibitors.

Figure 5

Structures are illustrated in similar conformations to facilitate comparison. Darunavir is shown with the P2, P1, P1’ and P2’ groups labeled. The modifications in the investigational inhibitors are indicated by black arrows. Antiviral inhibitors GRL-04410 and GRL-0519 have a methoxy substitution at P2’, while GRL-0519, GRL-04410 and GRL-05010 have tris-THF, methoxy and gem-difluoro additions at P2, respectively.